Several strong candidate genes and regions have been implicated in bipolar disorder (BP) and schizophrenia (SCZ) through linkage and association studies. These disorders have also recently been studied in genomewide association studies (GWAS), identifying further putative candidate loci, albeit with lower levels of significance and reproducibility than in GWAS of other complex disorders. 1 Our study focuses on a well-established candidate region for psychiatric illness and independently implicates one of the top candidate genes to emerge from GWAS of BP.
The chromosome 4p15-p16 linkage region was first identified in a large Scottish family multiply affected with major affective disorder. 2, 3 Subsequently, it has been repeatedly implicated in BP, SCZ and related phenotypes by linkage, association (reviewed in Le Hellard et al. 3 ) and GWAS. 4 We sought to refine the 20-Mb linkage region (delineated into four subregions A-D 3 ) in search of a susceptibility gene(s) by (1) performing a joint analysis of previously identified putative regions of association in regions B and D 5 in a combined sample of 600 BP patients, 681 SCZ patients and 765 controls from the Scottish population and (2) screening, for the first time, the remainder of the linkage region (regions A and C) for association in a sample of 506 BP patients, 576 SCZ patients and 607 controls from the Scottish population. We tested single markers and sliding windows of haplotypes in the BP, SCZ and combined samples, and stratified by gender, using 633 haplotype-tagging single-nucleotide polymorphisms (SNPs), and refined the region to 16 putative regions of association (B3 Mb), which met pre-determined, region-wide significance thresholds, following a method previously described and validated in Christoforou et al. 5 ( Figure 1 , Supplementary Material). Eight genes map directly to these regions, including, in particular, the SORCS2 gene, which maps within, or close to, four of the region A putatively associated regions and contains the most significant single-marker result in regions A and C (rs766008: P = 0.00030; OR C/A = 1.4, 95% confidence interval: 1.2-1.8).
The SORCS2 gene was first identified in a GWAS of BP, 4 in which it was the second best hit. Three SORCS2 SNPs (rs4411993, rs7683874 and rs10937823) showed evidence of association in two independent samples, with the same alleles conferring the increase in risk in both samples (best P = 0.000014 in the combined sample). 4 SNP rs4411993 was subsequently analyzed as part of a meta-analysis, in which it showed a trend towards significance (P = 0.054). 6 We also tested these three SNPs and identified nominal evidence of association to BP with rs7683874 (P = 0.024) and rs10937823 (P = 0.031), but with the opposite alleles conferring the increase in risk. In a replication study of the 26 SNPs with strongest association from the three GWAS of BP, Ollila et al. also reported nominal association to these three SORCS2 SNPs (best P = 0.0042) in a Finnish familybased cohort, with the same alleles as in our study conferring the increase in risk. Although this 'flip-flop' association may suggest spurious findings, it could also be a result of allelic heterogeneity, multi-locus effects or variable LD patterns between the samples, as, for example, observed between the GAPDH gene and Alzheimer's disease, owing to the variable interlocus correlation between the GAPDH and APOE e4 alleles in two different samples.
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SORCS2 plays a regulatory role in neurons, making it a strong functional candidate gene for psychiatric illness. It is thought to be involved in both internalizing surfacebound ligands and in intracellular trafficking processes. It is highly expressed during development and in the mature central nervous system, in a transient and dynamic manner, in regions of proliferation and differentiation. In the mature brain, expression is mainly neuronal in the cerebral cortex, hippocampus and cerebellum, where it is believed to be involved in the regulation of protein transport and is predicted to have a critical impact on neuronal viability and function. 9 In conclusion, we refine the chromosome 4p linkage region for BP and related phenotypes, identifying candidate genes and regions worthy of further investigation through meta-or mega-analyses 10 of available association data, additional replication, further finemapping, deep sequencing and/or functional studies to help rule out the false-positives and identify the true susceptibility gene(s). Most importantly, this study provides independent evidence of association for SORCS2, one of the top candidate genes to emerge from GWAS of BP, illustrating an instance of convergence of the findings of a hypothesis-based study of a well-supported susceptibility region with those of a hypothesis-free genome-wide approach.
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The authors declare no conflict of interest. First, the haplotype tagging (ht) SNPs genotyped and tested for association in this study. Second, the putative regions of association (and region-wide 'Nyholt-corrected' significance thresholds). Each putative region of association is indicated by a label (ai, aii, etc.), which corresponds to those in the supplementory online material (SOM) tables and text. The best P-value for each region of association is also provided. For region (a), there is an additional track, showing the location of the three SNPs reported by and their P-values in our study. *The only signle marker to meet its region-wide significance threshold in the second part of the study. **The two Baum et al. SORCS2 SNPs identified as nominally significant in our study. Panic disorder (PD) is a serious and common psychiatric condition 1 characterized mainly by recurrent episodes of intense, uncontrollable fear known as panic attacks. 2 The underlying causal mechanism for PD is unknown; 3 however, the discovery that drugs with clinical effectiveness against PD preferentially alter rodent flight behaviour suggests that PD reflects alterations in the brain systems that govern flight. 4 An association between PD and flight in humans is supported anecdotally by the tendency for PD sufferers to feel a strong urge to flee from the location where a panic attack occurs. 2 Here we provide the first human empirical evidence for a PD-flight link, showing that flight behaviour is significantly more intense in carriers of a candidate genetic risk factor for PD than in non-carriers.
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Human flight behaviour was measured using a computerized translation of a rodent runway task (Figure 1a ) designed to index fear proneness behaviourally, as the intensity of flight effort in response to a pursuing threat stimulus. 5 The genetic risk factor for PD used in this study was the C allele of the 102T/C single-nucleotide polymorphism (rs6313) within the serotonin 2a receptor gene (HTR2A) on chromosome 13q14.2; the C allele in this SNP is known to be associated with increased susceptibility to pure but not co-morbid PD, 6 as well as to increased intensity of panic symptoms. 7 All 200 participants (107 of whom were male) gave informed consent and self-identified as healthy Caucasians. Buccal cells were collected and DNA extracted using established methods (see Supplementary Information) .
The genotype distribution of rs6313 SNP in HTR2A was in Hardy-Weinberg equilibrium (w 2 = 0.632, d.f. = 2, P = 0.73). There were no significant genotype effects on flight intensity (F(1, 192) = 2.69, P = 0.070); however, carriers of the C risk allele showed significantly greater flight intensity than TT individuals (F(1, 194) = 4.90, P = 0.033; Figure 1b) . The construct validity of flight intensity as a specific measure of fear proneness was supported by its significant positive association with scores on tissue damage fear (measured by the Fear Survey Schedule) (F(1, 194) = 5.92, P = 0.022). The construct validity of flight intensity was also supported by the absence of a significant association with scores on Spielberger trait anxiety (F(1, 194) = 0.01, P = 0.998), which is a widely accepted questionnaire measure of anxiety proneness. 8 Sex did not affect flight intensity in this model (F(1, 194) = 1.50, P = 0.222), nor was there a significant allele Â sex interaction (F(1, 194) = 1.56, P = 0.213). There was no significant interaction between tissue damage fear and rs6313 carrier status (C carrier or TT homozygote) (F(1, 191) = 0.44, P = 0.511).
In overview, therefore, our study is the first molecular genetic investigation of human defensive behaviour and the first study empirically to support in humans the hypothesis that PD stems from alterations in the brain systems governing flight behaviour. However, although the HTR2A gene on chromosome 13q4-21 has previously been associated with PD, as a caveat it should be noted that the rs6313 SNP in exon 1 of the coding sequence of the HTR2A gene is a synonymous (or silent) polymorphism. Therefore, its previously observed effects at the phenotypic level may be mediated not by changes in protein structure but by other mechanisms such as gene expression. As rs6313 is part of a four-SNP haplotype (rs6311, rs1328674, rs6313, rs6314), future attempts at understanding
